Cargando…

Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease

PURPOSE: The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer’s disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Mark E., Janssens, Luc, Moechars, Diederik, Rombouts, Frederik J. R., Timmers, Maarten, Barret, Olivier, Constantinescu, Cristian C., Madonia, Jennifer, Russell, David S., Sandiego, Christine M., Kolb, Hartmuth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680304/
https://www.ncbi.nlm.nih.gov/pubmed/32535652
http://dx.doi.org/10.1007/s00259-020-04880-1
_version_ 1783612430658568192
author Schmidt, Mark E.
Janssens, Luc
Moechars, Diederik
Rombouts, Frederik J. R.
Timmers, Maarten
Barret, Olivier
Constantinescu, Cristian C.
Madonia, Jennifer
Russell, David S.
Sandiego, Christine M.
Kolb, Hartmuth
author_facet Schmidt, Mark E.
Janssens, Luc
Moechars, Diederik
Rombouts, Frederik J. R.
Timmers, Maarten
Barret, Olivier
Constantinescu, Cristian C.
Madonia, Jennifer
Russell, David S.
Sandiego, Christine M.
Kolb, Hartmuth
author_sort Schmidt, Mark E.
collection PubMed
description PURPOSE: The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer’s disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. We report the dosimetry of [(18)F] JNJ-64326067 and results of a proof-of-concept study comparing subjects with probable Alzheimer’s disease to age-matched healthy controls. METHODS: [(18)F] JNJ-64326067 PET scans were acquired for 90 min and then from 120 to 180 min in 5 participants with [(18)F]-florbetapir PET amyloid positive probable AD (73 ± 9 years) and 5 [(18)F]-florbetapir PET amyloid negative healthy controls (71 ± 7 years). Whole-body [(18)F] JNJ-64326067 PET CT scans were acquired in six healthy subjects for 5.5 h in 3 scanning sessions. Brain PET scans were visually reviewed. Regional quantification included kinetic analysis of distribution volume ration (DVR) estimated by Logan graphical analysis over the entire scan and static analysis of SUVr in late frames. Both methods used ventral cerebellar cortex as a reference region. RESULTS: One of the healthy controls had focal areas of PET signal in occipital and parietal cortex underlying the site of a gunshot injury as an adolescent; the other four healthy subjects had no tau brain signal. Four of the 5 AD participants had visually apparent retention of [(18)F] JNJ-64326067 in relevant cortical regions. One of the AD subjects was visually negative. Cortical signal in visually positive subjects approached steady state by 120 min. Temporal and frontal cortical SUVr/DVR values in visually positive AD subjects ranged from 1.21 to 3.09/1.2 to 2.18 and from 0.92 to 1.28/0.91 to 1.16 in healthy controls. Whole-body effective dose was estimated to be 0.0257 mSv/MBq for females and 0.0254 mSv/MBq for males. CONCLUSIONS: [(18)F] JNJ-64326067 could be useful for detection and quantitation of tau aggregates. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04880-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7680304
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-76803042020-11-23 Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease Schmidt, Mark E. Janssens, Luc Moechars, Diederik Rombouts, Frederik J. R. Timmers, Maarten Barret, Olivier Constantinescu, Cristian C. Madonia, Jennifer Russell, David S. Sandiego, Christine M. Kolb, Hartmuth Eur J Nucl Med Mol Imaging Original Article PURPOSE: The accumulation of misfolded tau is a common feature of several neurodegenerative disorders, with Alzheimer’s disease (AD) being the most common. Earlier we identified JNJ-64326067, a novel isoquinoline derivative with high affinity and selectivity for tau aggregates from human AD brain. We report the dosimetry of [(18)F] JNJ-64326067 and results of a proof-of-concept study comparing subjects with probable Alzheimer’s disease to age-matched healthy controls. METHODS: [(18)F] JNJ-64326067 PET scans were acquired for 90 min and then from 120 to 180 min in 5 participants with [(18)F]-florbetapir PET amyloid positive probable AD (73 ± 9 years) and 5 [(18)F]-florbetapir PET amyloid negative healthy controls (71 ± 7 years). Whole-body [(18)F] JNJ-64326067 PET CT scans were acquired in six healthy subjects for 5.5 h in 3 scanning sessions. Brain PET scans were visually reviewed. Regional quantification included kinetic analysis of distribution volume ration (DVR) estimated by Logan graphical analysis over the entire scan and static analysis of SUVr in late frames. Both methods used ventral cerebellar cortex as a reference region. RESULTS: One of the healthy controls had focal areas of PET signal in occipital and parietal cortex underlying the site of a gunshot injury as an adolescent; the other four healthy subjects had no tau brain signal. Four of the 5 AD participants had visually apparent retention of [(18)F] JNJ-64326067 in relevant cortical regions. One of the AD subjects was visually negative. Cortical signal in visually positive subjects approached steady state by 120 min. Temporal and frontal cortical SUVr/DVR values in visually positive AD subjects ranged from 1.21 to 3.09/1.2 to 2.18 and from 0.92 to 1.28/0.91 to 1.16 in healthy controls. Whole-body effective dose was estimated to be 0.0257 mSv/MBq for females and 0.0254 mSv/MBq for males. CONCLUSIONS: [(18)F] JNJ-64326067 could be useful for detection and quantitation of tau aggregates. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04880-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-06-13 2020 /pmc/articles/PMC7680304/ /pubmed/32535652 http://dx.doi.org/10.1007/s00259-020-04880-1 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Schmidt, Mark E.
Janssens, Luc
Moechars, Diederik
Rombouts, Frederik J. R.
Timmers, Maarten
Barret, Olivier
Constantinescu, Cristian C.
Madonia, Jennifer
Russell, David S.
Sandiego, Christine M.
Kolb, Hartmuth
Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
title Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
title_full Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
title_fullStr Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
title_full_unstemmed Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
title_short Clinical evaluation of [(18)F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer’s disease
title_sort clinical evaluation of [(18)f] jnj-64326067, a novel candidate pet tracer for the detection of tau pathology in alzheimer’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680304/
https://www.ncbi.nlm.nih.gov/pubmed/32535652
http://dx.doi.org/10.1007/s00259-020-04880-1
work_keys_str_mv AT schmidtmarke clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT janssensluc clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT moecharsdiederik clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT romboutsfrederikjr clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT timmersmaarten clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT barretolivier clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT constantinescucristianc clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT madoniajennifer clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT russelldavids clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT sandiegochristinem clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease
AT kolbhartmuth clinicalevaluationof18fjnj64326067anovelcandidatepettracerforthedetectionoftaupathologyinalzheimersdisease